SCHEMBL3003103

SCHEMBL3003103

COc1ccc(Br)cc1S(=O)(=O)N1CCN(c2nc(-c3ccc(C)c(C)c3)cs2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.52
MAPT P10636 5/20 0.49
RECQL P46063 3/20 0.49
USP2 O75604 2/20 0.49
HSD17B10 Q99714 1/20 0.49
SMN1; SMN2 Q16637 5/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
ALDH1A1 P00352 4/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
ALOX15 P16050 1/20 0.45
KDM4E B2RXH2 1/20 0.45
NTSR1 P30989 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
LMNA P02545 2/20 0.45
POLB P06746 1/20 0.45
MAPK1 P28482 3/20 0.45
PTPN1 P18031 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3648033 0.94 MAPT (0.48) GAAMAPTRECQLUSP2HSD17B10
SCHEMBL3013965 0.92 SMN1; SMN2 (0.59) GAAMAPTRECQLUSP2HSD17B10
SCHEMBL3011013 0.91 GAA (0.54) GAAMAPTRECQLUSP2HSD17B10
SCHEMBL3014448 0.90 MAPT (0.56) MAPTRECQLUSP2HSD17B10SMN1; SMN2
SCHEMBL3006383 0.89 ALDH1A1 (0.52) MAPTRECQLUSP2HSD17B10SMN1; SMN2
SCHEMBL3019571 0.89 GAA (0.52) GAAMAPTRECQLUSP2HSD17B10
SCHEMBL3011599 0.89 GAA (0.54) GAAMAPTRECQLUSP2HSD17B10
SCHEMBL3018355 0.89 MAPT (0.57) GAAMAPTRECQLUSP2HSD17B10
SCHEMBL3011654 0.89 POLB (0.56) GAAMAPTRECQLUSP2HSD17B10
SCHEMBL3011600 0.89 MAPT (0.51) GAAMAPTRECQLUSP2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA GAA 110/4885MAPT 18/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.